Jingzhun Medical Secures RMB 200 Million Series C Financing to Strengthen Leadership in Hematological Molecular Diagnostics

VCBeat (WeChat: VCBEAT) has learned that Beijing GenomePrecision Technology CO.,LTD. (“GenomePrecision” or the “Company”), a rare domestic provider of comprehensive molecular diagnostic solutions for hematologic diseases, announced today the completion of its Series C financing round of approximately RMB 200 million. The round was co-led by Shanghai Sunland Investment Management Co., Ltd. and Beijing Zhongguancun Co-Innovative Fund Management Co., Ltd., with participation from Yinhe Yuanhui Investment Co. Ltd. and Guiyang Venture Capital Co.,ltd. Existing investors Shenzhen Oriental Fortune Capital Co., Ltd. and Zhejiang Juren Capital Management Company continued to increase their stakes.

China Renaissance served as the exclusive financial advisor to Beijing GenomePrecision Technology CO.,LTD in this transaction.

This round of financing will be primarily used to further advance large-scale clinical trials and regulatory filings for the company’s molecular diagnostic reagent products, strengthen marketing efforts, accelerate the replication of its comprehensive solutions in core tertiary hospitals to secure market share, rapidly increase sales revenue, and complete the development of innovative products, thereby consolidating the company’s leading position in the field of molecular diagnostics for hematologic diseases.

Beijing GenomePrecision Technology CO.,LTD was founded in 2015. To date, it has established six major technology platforms to address the molecular diagnostic needs for hematological disorders in hospitals at all levels. The company is capable of providing a comprehensive suite of real-time fluorescent quantitative PCR, first-generation Sanger sequencing, second-generation high-throughput NGS sequencing, capillary electrophoresis fragment analysis, flow cytometry analysis, as well as related equipment and reagents for visualized molecular pathology testing. The company has pioneeredHematologic Malignancies, Transplantation, Novel Molecular Pathology, Cellular ImmunotherapyFour Major Domains: Providing comprehensive molecular diagnostics and monitoring solutions, along with corresponding product portfolios and service chains, to support the full spectrum of in-hospital testing needs for blood diseases at hospitals of all levels, including detection, diagnosis, treatment efficacy evaluation, and prognosis monitoring.

China currently has a prevalent population of over 4 million patients with hematologic malignancies, with more than 200,000 new cases of leukemia and lymphoma diagnosed annually. As various targeted therapies and cellular immunotherapies gain wider adoption, hematologic diseases are gradually transitioning into chronic conditions requiring long-term management, thereby unlocking substantial market potential for diagnosis and relapse monitoring. In light of the current landscape characterized by fragmented reagent supplies, a multitude of required technical platforms, and the relative operational independence of hematology departments,The company focuses on hematology departments in hospitals at all levels, innovatively practicing and summarizing the "Holistic Solution Model." It adopts strategies such as bundling core registered products with peripheral product portfolios for hospital admission, offering flexible combinations of testing equipment and reagent packages, and simultaneously pursuing innovative academic research collaborations and joint talent development within departments. These measures provide highly personalized and targeted project-based sales strategies to deeply bind hematology clients.During the initial phase of rapid market expansion, the company will leverage its foundation in Sichuan, Guizhou, Yunnan, and Chongqing to swiftly extend its reach into Central and East China. The company expects to obtain six Class III registration certificates for molecular diagnostics of hematologic diseases in 2021, and to increase the number of such certificates to over 30 by the end of 2024. This will position the company as the industry leader with the largest portfolio of registration certificates and the broadest coverage in the field of molecular diagnostics for hematologic diseases, thereby establishing a strong competitive barrier.

Professor Ye Feng, Founder of GenomePrecisionstated: “We are deeply honored to have gained the recognition and support of renowned domestic investment institutions and existing shareholders. Hematologic malignancies in China predominantly affect young adults, adolescents, and children, a demographic with strong demand for diagnosis and treatment as well as high willingness to pay. The rapid increase in testing penetration is creating a substantial new market. As a rare supplier in the industry capable of providing comprehensive solutions, and with an anticipated surge in regulatory approvals in the coming years coupled with strong capital backing, our sales volume is poised for sustained growth, positioning us to become an industry leader.”

Nie Hongxin, Managing Partner of Sunland Capital“He stated: ‘The classification of hematologic diseases is complex, and product demands are fragmented. However, against the backdrop of precision medicine, multi-platform, multi-parameter testing has become a clinical necessity, with its penetration rate rising rapidly. GenomePrecision focuses on hematology, providing comprehensive end-to-end solutions for the diagnosis and treatment of hematologic diseases to efficiently meet diverse clinical needs. The founding team remains committed to deepening its expertise in this niche sector. It not only demonstrates strong execution capabilities in refining product performance to closely align with actual clinical needs but also leads the industry in business model innovation. Through this investment, Shanghai Sunland Investment Management Co., Ltd. further diversifies its portfolio in the IVD sector. We look forward to leveraging Sunland Capital’s industry resources and experience to support the company’s growth, enabling more and better innovative medical products to benefit a broader patient population.’”

Dong Hao, Managing Director of Zhongguancun Co-Innovation Fundstated: “The Jingshun Medical team has extensive and successful experience in product R&D and commercialization, market positioning, and sales promotion. We are optimistic about the company’s comprehensive ‘platform products + services’ solution package and look forward to more milestone achievements following this round of financing.” Mo Jiuchao, the project leader, also remarked: “Empowered comprehensively by the industrial resources of Zhongguancun Development Group, Jingshun Medical’s full-platform products will surely establish brand advantages rapidly and secure a stronger market position.”

Chen Huawei, Partner at Oriental Fortune Capitalstated: “GenomePrecision Medical is an early-stage investment of ours. The founder, Professor Ye, is a senior expert in molecular diagnostics in China, and the team possesses strong capabilities in technological R&D and market promotion. The company is currently a leading platform enterprise in this field. This successful financing round will accelerate product registration and market expansion, propelling the company to a new level of development.”

As the investment banking advisor for this transaction,Li Jin, Managing Director of China Renaissance Capitalstated: “GenomePrecision is a rare domestic enterprise capable of establishing in-hospital molecular diagnostic laboratories for hematologic diseases and providing related services, centered around the hematology departments of hospitals at all levels. We greatly appreciate Professor Ye Feng, the company’s founder, for his exceptional expertise in molecular diagnostics for hematologic diseases and his strong business development capabilities. Professor Ye’s years of focus and professionalism have laid a solid technological and product foundation for the company. With the continuous approval of registration certificates, the company is poised to leverage its accumulated strengths and enter a phase of rapid growth. We are pleased to have assisted the company in completing this round of financing and look forward to seeing it accelerate product R&D and regulatory submissions post-financing, thereby benefiting more patients.”

Sunland Capital is a specialized fund focused on investing in the early and growth stages of the healthcare industry, with an emphasis on high-growth segments such as biopharmaceuticals, medical devices (including in vitro diagnostics and gene technologies, minimally invasive interventions, implantable devices, minimally invasive surgical instruments, and medical robots), and healthcare services. The core team at Sunland Capital comprises founders of publicly listed healthcare companies, as well as professional financial and strategic investors. The firm provides value-added services to its portfolio companies across various domains, including strategy formulation, talent acquisition, R&D, marketing, legal and regulatory compliance, mergers and acquisitions, IPOs, and industry association resources. Additionally, Sunland Capital assists portfolio companies in integrating advanced international technologies and establishing global operational philosophies and standards, thereby facilitating their continuous innovation and development.

The Zhongguancun Co-Innovation Fund was jointly established by Zhongguancun Development Group, along with 15 local governments and financial institutions from nine provinces and municipalities. It operates under market-oriented mechanisms and adopts a “1+1+N” model, comprising one fund of funds, one direct-investment sub-fund series, and N co-innovation sub-funds, with a total scale of RMB 10 billion.

Yinhe Yuanhui Investment Co., Ltd. was established on December 10, 2015. As a wholly-owned alternative investment subsidiary of China Galaxy Securities Co., Ltd., it has a registered capital of RMB 3 billion and utilizes its own funds to focus on equity investments and financial product investments.

Guiyang Venture Capital Co., Ltd. is a controlling subsidiary established by Guiyang Industrial and Commercial Investment Group Co., Ltd. It was founded by the Group as a specialized service institution engaged in venture capital and equity investment, with the aim of building a leading domestic non-banking financial services provider. The company’s business activities include: venture capital and equity investment; financing and management consulting; acting as an agent for other investment institutions or individuals to manage funds; and initiating the establishment of equity investment funds and fund management companies, among others. To date, the company has initiated multiple funds with a total scale exceeding RMB 5 billion and has successfully completed numerous investment cases.

Shenzhen Oriental Fortune Capital Co., Ltd. (hereinafter referred to as “OFC” or “Oriental Fortune Capital”) is a professional venture capital management firm founded by several industry experts with extensive experience, proven track records, and significant influence in China’s venture capital sector. Established in 2006, OFC manages assets under management exceeding RMB 25 billion. The firm is committed to investing in high-growth companies with IPO potential, actively providing value-added services to its portfolio companies to enhance their profitability, and striving to help them maximize corporate value through exits such as initial public offerings (IPOs).

Zhejiang Juren Capital Management Company was established in 2013 with a registered capital of RMB 50 million. It was founded by eight leading industry enterprises in Zhejiang Province as shareholders, and primarily engages in equity investment, mergers and acquisitions, restructuring, and strategic consulting services. The company currently manages assets totaling RMB 3 billion, focusing on high-tech enterprises in the growth and mature stages within sectors such as healthcare, advanced manufacturing, and TMT (Technology, Media, and Telecommunications).